tadalafil

URI: https://gptkb.org/entity/tadalafil
GPTKB entity
Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:drug
phosphodiesterase type 5 inhibitor
gptkbp:approvalYear 2003
gptkbp:ATCCode G04BE08
gptkbp:availableGeneric yes
gptkbp:availableOn gptkb:tablet
gptkbp:brand gptkb:Cialis
gptkb:Adcirca
gptkbp:CASNumber 171596-29-5
gptkbp:chemicalClass beta-carboline
gptkbp:contraindication nitrate medications
severe cardiovascular disorders
gptkbp:developedBy gptkb:Eli_Lilly
gptkb:ICOS
gptkbp:discoveredBy gptkb:Glenn_Wood
gptkbp:drugInteraction CYP3A4 inhibitors
nitrates
alpha-blockers
antihypertensives
gptkbp:effect increases blood flow to penis
relaxes smooth muscle in blood vessels
gptkbp:eliminationHalfLife 17.5 hours
gptkbp:excretion urine
feces
gptkbp:firstSynthesized 1993
gptkbp:hasMolecularFormula C22H19N3O4
https://www.w3.org/2000/01/rdf-schema#label tadalafil
gptkbp:IUPACName (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
gptkbp:legalStatus prescription only
gptkbp:marketedAs gptkb:Eli_Lilly
gptkb:ICOS
gptkbp:mechanismOfAction inhibits PDE5 enzyme
gptkbp:meltingPoint 298–300 °C
gptkbp:metabolism liver (CYP3A4)
gptkbp:notRecommendedFor children
gptkbp:patentExpired 2017 (US)
gptkbp:pregnancyCategory B (US)
gptkbp:prescribes adults
gptkbp:routeOfAdministration oral
gptkbp:sideEffect headache
back pain
muscle aches
nasal congestion
dyspepsia
flushing
gptkbp:solubility practically insoluble in water
gptkbp:usedFor gptkb:benign_prostatic_hyperplasia
erectile dysfunction
pulmonary arterial hypertension
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:CYP3A4
gptkbp:bfsLayer 5